Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 9976
Country/Region: Vietnam
Year: 2017
Main Partner: Ministry of Health - Vietnam
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $5,068,269 Additional Pipeline Funding: $1,806,333

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $129,592
Care: TB/HIV (HVTB) $200,958
Care: Pediatric Care and Support (PDCS) $66,861
Laboratory Infrastructure (HLAB) $50,000
Strategic Information (HVSI) $50,000
Health Systems Strengthening (OHSS) $65,889
Testing: HIV Testing and Counseling (HVCT) $1,427,873
Sexual Prevention: Other Sexual Prevention (HVOP) $100,000
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $120,291
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $90,179
Treatment: Adult Treatment (HTXS) $2,684,082
Treatment: Pediatric Treatment (PDTX) $82,544
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 23,717
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 84,404
HTS_TST Service Delivery Point Agg Age (Community) Other: 15+, Female, Negative 2018 558
HTS_TST Service Delivery Point Agg Age (Community) Other: 15+, Male, Negative 2018 1,148
HTS_TST Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative 2018 6,163
HTS_TST Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative 2018 14,580
HTS_TST Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative 2018 19,249
HTS_TST Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative 2018 25,252
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative 2018 14,678
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative 2018 22,798
HTS_TST Sum of Test Result disaggregates 2018 1,290
HTS_TST Sum of Test Result disaggregates 2018 2,443
HTS_TST_POS By Test Result: Positive 2018 1,290
HTS_TST_POS By Test Result: Positive 2018 2,443
HTS_TST_POS Service Delivery Point Agg Age (Community) Other: 15+, Female, Positive 2018 12
HTS_TST_POS Service Delivery Point Agg Age (Community) Other: 15+, Male, Positive 2018 48
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive 2018 346
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive 2018 862
HTS_TST_POS Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive 2018 282
HTS_TST_POS Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive 2018 655
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive 2018 473
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive 2018 1,017
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2018 5,620
KP_MAT Sex: Female 2018 77
KP_MAT Sex: Male 2018 5,543
KP_MAT Sum of Sex Disaggregates 2018 5,620
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 2,204
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 977
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 17,381
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 2,742
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 23,304
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 245
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 271
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 59
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 92
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 178
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 163
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 5
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 11
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 3
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 5
PP_PREV Age/sex: 15-19 Female 2018 979
PP_PREV Age/sex: 20-24 Female 2018 1,793
PP_PREV Age/sex: 20-24 Male 2018 491
PP_PREV Age/sex: 25-49 Female 2018 15,323
PP_PREV Age/sex: 25-49 Male 2018 1,953
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 20,539
PP_PREV Sum of Age/Sex disaggregates 2018 20,539
TB_PREV By Age/Sex (Numerator): <15, Female 2018 23
TB_PREV By Age/Sex (Numerator): <15, Female 2018 19
TB_PREV By Age/Sex (Numerator): <15, Male 2018 26
TB_PREV By Age/Sex (Numerator): <15, Male 2018 25
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 288
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 354
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 428
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 585
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 765
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 983
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 962
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 1,223
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 33
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 25
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 32
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 31
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 362
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 435
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 535
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 732
TX_CURR Aggregated Age/Sex: <15 Female 2018 457
TX_CURR Aggregated Age/Sex: <15 Female 2018 476
TX_CURR Aggregated Age/Sex: <15 Male 2018 459
TX_CURR Aggregated Age/Sex: <15 Male 2018 570
TX_CURR Aggregated Age/Sex: 15+ Female 2018 4,471
TX_CURR Aggregated Age/Sex: 15+ Female 2018 5,775
TX_CURR Aggregated Age/Sex: 15+ Male 2018 6,497
TX_CURR Aggregated Age/Sex: 15+ Male 2018 9,467
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 11,884
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 16,288
TX_CURR Sum of Aggregated Age/Sex <15 2018 916
TX_CURR Sum of Aggregated Age/Sex <15 2018 1,046
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 10,968
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 15,242
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 11,884
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 16,288
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 40
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 31
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 39
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 36
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 449
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 551
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 671
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 916
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 1,199
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 1,534
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 1,199
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 1,534
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 10,697
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 14,661
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 9,626
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 13,193
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 370
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 386
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 373
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 462
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 3,618
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 4,677
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 5,265
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 7,668
TX_PVLS Numerator: Indication: Routine 2018 9,626
TX_PVLS Numerator: Indication: Routine 2018 13,193
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 412
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 430
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 412
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 513
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 4,025
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 5,195
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 5,848
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 8,523
TX_PVLS_den Denominator: Indication: Routine 2018 10,697
TX_PVLS_den Denominator: Indication: Routine 2018 14,661
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 33
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 26
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 34
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 31
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 373
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 453
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 555
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 763
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 995
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 1,273
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 1,079
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 1,383
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 34
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 27
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 36
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 34
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 406
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 498
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 603
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 824
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 11,291
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 15,473
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 244
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 145
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 9
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 3
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 9
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 4
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 93
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 54
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 133
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 84
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 434
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 451
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 437
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 543
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 4,246
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 6,174
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 5,484
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 8,995
Cross Cutting Budget Categories and Known Amounts Total: $750,000
Key Populations: MSM and TG $150,000
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Gender: Gender Equality $100,000
Promoting gender-related policies and laws that increase legal protection
Human Resources for Health $500,000